Repligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer
Repligen Corporation (NASDAQ: RGEN) today announced that the first patient has been enrolled in a pilot study to evaluate the ability of RG1068 to improve detection and characterization of pancreatic cancer in combination with contrast-enhanced magnetic resonance imaging (MRI) and computed tomography. In addition, this study will evaluate which imaging technique is optimal for pancreatic tumor detection, staging and evaluation for surgery. This study will enroll up to 40 patients with a known or suspected pancreatic mass and the presence of a tumor will be confirmed by either surgery or biopsy.
Early detection of pancreatic cancer will increase the identification of patients who are candidates for surgery and may improve patient outcomes. This is an investigator-sponsored study lead by Pablo R. Ros, M.D., Chairman, Department of Radiology, University Hospitals Case Medical Center in Cleveland Ohio, affiliated with Case Western University.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.